𝔖 Bobbio Scriptorium
✦   LIBER   ✦

398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours

✍ Scribed by N. Lewis; R.B. Cohen; Y. Nishida; H.I. Hurwitz; C. Arrowwood; H.E. Uronis; F. Gamza; C. Longley; A. Buchbinder; J. Figueroa


Book ID
119599554
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
61 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.